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Background:The role of the type 2 diabetes risk gene SLC30A8, encoding ZnT8, in the control of glucagon secretion is not
clearly established.
Results: Inactivation of ZnT8 in a subset of -cells leads to increased glucagon secretion in vivo and in vitro.
Conclusion: ZnT8 is involved in normal glucagon release.
Significance: SLC30A8 diabetes risk alleles may influence glucagon secretion.
SLC30A8 encodes a zinc transporter ZnT8 largely restricted
to pancreatic islet - and -cells, and responsible for zinc accu-
mulation into secretory granules. Although common SLC30A8
variants, believed to reduce ZnT8 activity, increase type 2 dia-
betes risk in humans, rare inactivatingmutations are protective.
To investigate the role of Slc30a8 in the control of glucagon
secretion, Slc30a8was inactivated selectively in-cells by cross-
ing mice with alleles floxed at exon 1 to animals expressing Cre
recombinase under the pre-proglucagon promoter. Further
crossing to Rosa26:tdRFPmice, and sorting of RFP: glucagon
cells fromKOmice, revealed recombination in30% of-cells,
of which 50% were ZnT8-negative (14  1.8% of all -cells).
Although glucose and insulin tolerance were normal, female
ZnT8KO mice required lower glucose infusion rates during
hypoglycemic clamps and displayed enhanced glucagon release
(p < 0.001) versus WT mice. Correspondingly, islets isolated
from ZnT8KO mice secreted more glucagon at 1 mM glucose,
but not 17 mM glucose, than WT controls (n  5; p  0.008).
Although the expression of other ZnT family members was
unchanged, cytoplasmic (n 4 mice per genotype; p< 0.0001)
and granular (n 3, p< 0.01) free Zn2 levels were significantly
lower in KO -cells versus control cells. In response to low glu-
cose, the amplitude and frequency of intracellular Ca2
increases were unchanged in -cells of ZnT8KO KO mice.
ZnT8 is thus important in a subset of -cells for normal
responses to hypoglycemia and acts via Ca2-independent
mechanisms.
Glucagon is the key counter-regulatory hormone responsible
for opposing the glucose-lowering effects of insulin (1). Thus,
glucagon stimulates both glycogen breakdown and gluconeo-
genesis by the liver (2), whereas decreasing hepatic triglyceride
synthesis (3, 4). Strikingly, mice deleted for glucagon receptors
fail to develop hyperglycemia after the destruction of the -cell
complement (5), demonstrating the likely importance of main-
tained or increased glucagon signaling in the context of type 2
diabetes (T2D)4 (6, 7). By contrast, glucagon secretion is
required in type 1 diabetes to ensure an adequate response to
insulin-inducedhypoglycemia, and a failure of this process con-
tributes significantly to mortality in the latter disease (7).
Together, these diseases affect 6% of the population world-
wide (8).
Recent genome-wide association studies (9–12) have dem-
onstrated that 90 loci in the human genome significantly
affect the risk of T2D. Although the roles played by the genes in
these loci in the control of insulin secretion is under increasing
scrutiny using model systems (13, 14), an action to modulate
glucagon secretion is, in most cases, unexplored.
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The SLC30A8 gene, encoding the endocrine pancreas-re-
stricted zinc transporter ZnT8, displays one of the strongest
effect sizes on T2D risk (15% per allele). The risk (thymine)
variant at SNP rs13266634 encodes an R325W variant with
lower Zn2 transporting activity and thus less able to catalyze
the accumulation of Zn2 into insulin-containing granules
(15, 16).
Consistent with impaired -cell function in the absence of
ZnT8, we (15, 17) and others (18) have previously shown, using
CreLoxP technology, that inactivation of the Slc30a8 gene in
mice, either systemically (15, 17, 18) or selectively in the -cell
(19), leads to abnormal insulin release in vivo and impaired
glucose tolerance. This is associated with a profound loss of
total Zn2 from the -cell granule and a derangement in the
ultrastructure of dense cores, indicative of the failure of insulin
to crystallize. Furthermore, recent studies (20) suggest that
decreased Zn2 release from the pancreas, and consequently
enhanced insulin clearance by the liver, also contributes to
lower insulin levels (and an increase in C-peptide/insulin ratio)
in carriers of risk variants at SLC30A8.
Suggesting that the relationship between variants in
SLC30A8 and diabetes risk may be more complex than previ-
ously assumed, rare inactivating mutations in the SLC30A8
gene have been shown to protect against T2D (21), a result that
was unexpected given that inactivation of the gene inmice usu-
ally leads to impaired glucose tolerance (see above) (22). This
paradox has therefore led us to re-investigate whether there
may be a role for ZnT8 in glucagon storage and secretion.
Although our earlier studies of the metabolic phenotype of
mice in which ZnT8 inactivated selectively in the -cell did not
reveal a marked glycemic phenotype, notably during glucose
tolerance tests, the above studies were limited in scope and did
not examine the effects of ZnT8 deletion during hypoglycemia
(19).
The chief goal of the present work was therefore to re-ex-
plore the role of ZnT8 in the control of glucagon secretion and
to determine the molecular and cellular basis for any changes
identified. We have addressed these questions by combining
single cell imaging approaches and in vivo analyses of glucose
homeostasis in mice lacking the transporter selectively in the
-cell. We show that deletion of ZnT8 in a limited subset
(15%) of -cells is sufficient to increase glucagon secretion at
low glucose concentrations in vitro and in vivo and to improve
the response to hypoglycemia. Possible mechanisms through
which ZnT8 may restrict glucagon release are discussed.
Experimental Procedures
Animals—Animals were kept in a pathogen-free facility
under a 12-h light-dark cycle with access to water and a stan-
dardmouse diet (Lillico Biotechnology). The transgenic mouse
strains were maintained on a C57/BL6 genetic background.
Mice bearing alleles of ZnT8 (Slc30a8) in which exon 1 was
flanked by LoxP sites were obtained from genOway (Lyon,
France). To generate ZnT8 KOmice, ZnT8fl/fl mice (19) were
crossed to mice carrying the Cre transgene under an 0.6-kb
fragment of the pre-proglucagon promoter (PPGCre) (23).
Breeding pairs were established between PPGCre:ZnT8fl/fl and
ZnT8fl/fl mice, allowing comparison between Cre and Cre
littermates. Note that the presence of the PPGCre itself does
not impact glycemic phenotype (24) or lead to recombination
outside the pancreas (25). For selective labeling of -cells in in
vitro experiments, ZnT8 KO mice were further crossed to
Rosa26:tdRFP animals. Mice expressing the Cre transgene and
tdRFP with WT ZnT8 alleles (ZnT8/:PPGCre/:RFP)
were used as controls in experiments that required -cell iden-
tification (Ca2 and Zn2 imaging). For in vivo studies, and in
vitro experiments using islets that did not require -cell iden-
tification, ZnT8fl/fl:PPGCre/mice were used as controls. All
animal experiments were approved by the UK Home Office
under the Animals (Scientific Procedures) Act 1986 (PPL
70/7349).
FACS Analysis—Islets were dissociated into single cells as
described previously (26), washed in PBS, and centrifuged at
600 g for 2min. Cells were incubated in 50l of near-IR dead
cell stain (1:1000; Life Technologies) for 20min at 4 °C, washed
with PBA (PBS, 1% BSA, 0.1% azide), and fixed in 2% parafor-
maldehyde for 10 min at room temperature. Cells were then
washed twice with PBA and once with saponin (0.025% in PBA)
before a 10-min incubation with saponin at room temperature.
Cells were incubated with primary antibodies against mouse
ZnT8 (Mellitech, Grenoble, France) and insulin and glucagon
(DAKO and Santa Cruz Biotechnology, respectively) at 1:100
dilution in saponin for 20 min. After two further washes in
saponin, cells were incubated with secondary antibodies
(anti-mouse Alexa Fluor 405, anti-guinea pig Alexa Fluor
488, anti-rabbit Alexa Fluor 640) for 20 min. Two final
washes in saponin were performed before resuspension in
PBA. The samples were processed on a BD LSRFortessa flow
cytometer (BD Biosciences).
Islet Isolation—Islets were isolated essentially as described
(27), with minor modifications. Briefly, pancreata inflated with
collagenase solution at 1 mg/ml (Serva) were placed in a water
bath at 37 °C for 10 min. Cold additive-free RPMI (Sigma) was
added followed by centrifugation at 1000 rpm for 1 min. The
supernatant was removed before adding 15 ml of cold addi-
tive-free RPMI medium, and the pancreas was resuspended in
the medium. This pellet was washed three more times. The
islets were then re-suspended in 3 ml of Histopaque 119
(Sigma). A sucrose gradient was thenmade by adding dropwise
3 ml of Histopaque 1083 and 1077 (Sigma). Finally, RPMI was
added dropwise up to 12 ml. The gradient was centrifuged at
2500 rpm for 20min. The islets found just below theRPMI layer
were collected and centrifuged at 1000 rpm for 1 min after the
addition of up to 12ml of RPMI. The supernatant was removed;
islets were re-suspended and put in a Petri dish containing
complete RPMImedium.After a few hours of recovery at 37 °C,
islets were handpicked and placed in fresh medium.
Glucagon Secretion and Extraction of Total Pancreatic
Glucagon—Glucagon secretion was measured from groups of
18 size-matched islets per well, incubated for 1 h in 500 l of
Krebs-HEPES bicarbonate buffer at 37 °C and constant agita-
tion supplemented with either 1 mM or 17 mM glucose (26).
Total islet glucagon was extracted from islets using acidified
ethanol and sonication. Secreted and total glucagon were mea-
sured by radioimmunoassay (Millipore). Total pancreatic glu-
ZnT8 in Glucagon Secretion
AUGUST 28, 2015•VOLUME 290•NUMBER 35 JOURNAL OF BIOLOGICAL CHEMISTRY 21433
 at Im
perial College London on N
ovem
ber 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
cagon was extracted by homogenization in acid ethanol and
quantified by HTRF-based (CisBio) assay as described (28).
Glucose Tolerance Tests—Mice were fasted overnight before
intraperitoneal injection with glucose (1 g/kg). Blood samples
were subsequently taken from the tail vein at 0, 15, 30, 60 ,and
120 min, and glucose concentration was measured with an
automatic glucometer (Accucheck, RocheDiagnostics, Burgess
Hill, UK).
Insulin Tolerance Tests—Mice were fasted for 5 h before
intraperitoneal injection with insulin (0.5 units/kg) and blood
sampling at 0, 15, 30, and 60 min for glucose concentration as
above. Additionally,100l of plasma was taken at time 0 and
15 min for glucagon measurements using a radioimmunoassay
(Millipore).
Hyperinsulinemic/Hypoglycemic Clamp—Mice were injected
through a jugular catheter with an insulin bolus (1 units/kg) to
decrease glycemia to 50 mg/dl within 30–40 min. After this
bolus, animals were perfused with insulin at 1.2 units/kg/h for 90
min (3 l/min). Glucose (20%) was co-perfused with insulin to
maintain a plasma glucose level of 50mg/dl. The concentration of
blood glucose was measured every 20 min. Blood was collected
before and at the end of the clamp in tubes filled with EGTA (1.6
mg/ml, Sigma) and aprotinin (250 kilo-international units/ml;
Sigma) for glucagonmeasurement.
Calcium Imaging—Islets were incubated (37 °C 95% O2/5%
CO2) for 45 min in 10 M Fluo-2-AM (Invitrogen) dissolved in
DMSO (0.01% w/v) and pluronic acid (0.001% w/v) in a bicar-
bonate buffer containing (in mM) 120 NaCl, 4.8 KCl, 1.25
NaH2PO4, 24NaHCO3, 2.5 CaCl2, 1.2MgCl2, 3 D-glucose). Fol-
lowing incubation, islets were placed in a perifusion chamber,
mounted on a Zeiss Axiovert confocal microscope, and peri-
fused continuously at 34–36 °Cwith buffer containing the indi-
cated glucose concentration. Fluo-2 was excited with a 491-nm
laser, and emitted light was filtered at 525/50 nm. VolocityTM
software (PerkinElmer) was used for data capture and analysis.
Traces are presented as normalized intensity over time
(F/Fmin).
Cytosolic Zinc Imaging with FluoZin-3—Islets were incu-
bated (37 °C, 95% O2/5% CO2) for 1 h in 1 M FluoZin-3-AM
(Invitrogen) dissolved in DMSO (0.01% w/v) in bicarbonate
buffer containing 11mM glucose. Imaging was performed as for
Ca2, and results are presented as F1/Fmin where F1  mean
baseline fluorescence, and Fminminimum fluorescence in the
presence of the Zn2 chelatorN,N,N,N-tetrakis (2-pyridylm-
ethyl) ethylenediamine (TPEN).
GranularZinc ImagingwithZinpyr-4—Isletswere incubated
as above for 30 min in 10 M Zinpyr-4 (Santa Cruz Biotechnol-
ogy). Imaging was performed on aNikonTi Eclipsemicroscope
equipped with an X-Light spinning disk and Hamamatsu
ORCA-Flash4.0 complementary metal oxide semiconductor
detector. Static images were captured at 37 °C using a 63
objective, keeping the exposure time and laser intensity con-
stant throughout. Zinpyr-4 and RFP were excited using 488-
and 561-nm lasers, respectively, and signals were monitored at
535/50nm (Zinpyr-4) and 630/75nm (RFP).Differences inZin-
pyr4 intensity between WT and KO animals were measured
using the corrected total cell fluorescence (integrated density
(cell areamean background fluorescence)), as described (29).
Cell Sorting by FACS—After overnight incubation, 250–
300 islets were washed twice with 5 ml of Hanks’-based cell
dissociation buffer (Invitrogen) containing 0.1% BSA, before
centrifugation at 2000 rpm for 2 min. The islets were dissoci-
ated by repeated pipetting in 150l of the solution and 20l of
trypsin. The reaction was stopped with the addition of 20 l of
FBS (Seralab). Dissociated cells were then washed in 1 ml of
PBS, centrifuged, and resuspended in 500l of PBS and 1%FBS,
before the addition of DAPI (1 g/ml; Roche Diagnostics) to
stain for dead cells. Following a 10-min incubation, cells were
filtered through a 35-m strainer, and RFP and RFP cells
were recovered in 500-l TRIzol post-sorting on a BD FAC-
SAria III (BD Biosciences).
RNAExtraction—Cellswerewashed twice in PBS followed by
the addition of 500 l of TRIzol (Invitrogen). Chloroform (200
l/ml TRIzol) was added, and the tube was inverted 5–6 times
and left at room temperature for 5 min until two layers formed.
Samples were centrifuged at 12,000 rpm for 15min at 4 °C. The
upper aqueous phase was removed, and 2 l of glycogen was
added before precipitating RNA by adding an equal volume of
isopropanol, incubating for 15 min at room temperature, and
centrifuging for 15 min at 12,000 rpm. The pellet was washed
twice in 1 ml of 75% ethanol and centrifuged at 12,000 rpm for
5min. The dried pellet was finally resuspended in nuclease-free
water.
cDNA and RT-PCR—RNA was extracted using TRIzol and
cDNA transcribed using a High Capacity reverse transcription
kit (Applied Biosystems) according to the manufacturer’s
instructions. SYBRGreen quantitative RT-PCRwas performed
as described previously (30), using the primer sequences given
in Ref. 31 and Table 1.
Immunostaining—Pancreata were fixed in 10% formalin
overnight at 4 °C, embedded in wax, and sliced at 5 m. Sec-
tions were then dewaxed using Histoclear (Sigma) and rehy-
drated by washing in 100, 95, and 70% ethanol and distilled
water. The sections were treated with antigen unmasking solu-
TABLE 1
Additional primer sequences used for quantitative RT-PCR
FOR, forward; REV, reverse.
ZnT1 FOR CAGGCAGAGCCAGAAAAATTG
ZnT1 REV TGGATGAGATTCCCATTTACTTGTAC
ZnT2 FOR CCCGACCAGCCACCAA
ZnT2 REV CCAAGGATCTCGGCTCGAT
ZnT3 FOR GGAGGTGGTTGGTGGGTATTT
ZnT3REV CAAGTGGGCGGCATCAGT
ZnT4 FOR CATCGCTGCCGTCCTCTAC
ZnT4 REV ATTTGCCATGTATCCACCTACAAG
ZnT5 FOR ACTGTTTGCTGCCCTGATGAG
ZnT5 REV CTCTATTCGGCCATACCCATAGG
ZnT6 FOR ACGTCTCTGAAGCTGCTAGTACGA
ZnT6 REV CCACACAAGCTGCGGCTAA
ZnT7 FOR TGTGCCTGAACCTCTCTTTCG
ZnT7 REV GCCTAGGCAGTTGCTCCAGAT
ZnT8 FOR TGCACAGTCTACACATCTGGTCACT
ZnT8 REV TGGCTGGCAGCTGTAGCA
ZnT9 FOR GCACTGGGCATCAGCAAAT
ZnT9 REV GAAAAGCCGTACGGGTGAGA
MT1 FOR CCTTCTCCTCACTTACTCCGTAGC
MT1 REV GGAGCCGCCGGTGGA
MT2 FOR TCCTGTGCCTCCGATGGAT
MT2 REV TGCAGGAAGTACATTTGCATTGT
MT3 FOR AAGTGCAAGGGCTGCAAATG
MT3 REV CACAGTCCTTGGCACACTTCTC
Actin FOR CGAGTCGCGTCCACCC
Actin REV CATCCATGGCGAACTGGTG
ZnT8 in Glucagon Secretion
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tion (Vector Laboratories), before washing in PBS and blocking
in PBS containing 0.1% Triton X-100, 2% BSA, and 2% goat and
donkey serum for 60 min at room temperature. Primary anti-
bodies (anti-guinea pig insulin (Dako), 1:200, anti-rabbit gluca-
gon (Sigma), 1:100) in PBS were then applied overnight at 4 °C.
The next day, slides were washed three times in PBS, before
incubation with secondary antibodies (Alexa Fluor 488 goat
anti-guinea pig 1:1000, Alexa Fluor 568 donkey anti-rabbit
1:500) in PBS at room temperature, and mounting using
VECTASHIELD with DAPI. Imaging was performed using a
Zeiss Axio Observer widefield microscope using a 40 objec-
tive. The :-cell ratio was determined by subjecting insulin
and glucagon immunopositive regions to manual thresholding
(ImageJ macro) and dividing the -cell area by the -cell area.
For analysis of the subcellular distribution of ZnT8 and gluca-
gon, islets were dissociated into single cells with trypsin (Hanks’
buffer, Invitrogen, Paisley, UK) and, after fixation in 4% (v/v)
paraformaldehyde and permeabilization with Triton X-100 as
above, treated with anti-ZnT8 (1:200; Mellitech) and anti-glu-
cagon (1:1,000) antibodies, in PBS containing 1% (w/v) BSA
before mounting. Images were captured with a Zeiss Axiovert
confocal microscope (32) using a 63 objective.
Statistical Analysis—Student’s t test was used to identify the
significance of any difference between two independent vari-
ables. Interactions between multiple treatments were deter-
mined using two-wayANOVA (adjusted for repeatedmeasures
as appropriate), followed by pairwise comparisonswith Bonfer-
roni’s post hoc test. All analyses were performed using
GraphPad Prism 6.0, and results were considered significant at
p 0.05. Values are presented as means	 S.E.
Results
Recombination and Deletion of ZnT8 in the -Cell—To
investigate the role of ZnT8 in the -cell, we generated and
studied mice deleted selectively in the -cell for ZnT8. Inacti-
vation was achieved using Cre recombinase under the control
of the pre-proglucagon promoter (PPGCre) (23) to delete the
first exon of the Slc30a8 gene. For in vivo studies, littermate
controls were used as generated under Fig. 1A (i). To allow
identification of -cells in these islets in in vitro experiments,
the resulting mice were further crossed with animals bearing
tdRFP 3 to a stop-flox-stop cassette at the Rosa26 locus
(Rosa26tdRFP; Fig. 1A (ii)). A separate colony of animals, WT
for the Slc30a8 locus, was bred bearing theRosa26:tdRFP trans-
gene and PPGCre, for use as controls in in vitro experiments
(Fig. 1A (iii)). PCR amplification of DNA extracted from ear
biopsies was performed to determine genotype (e.g. Fig. 1B).
There were no apparent differences in growth and body weight
between WT and KO animals (not shown).
We have previously reported (33), using islets from
RFPPPGCre/ mice and staining for RFP and glucagon or
insulin, that 45% of glucagon-positive cells expressed RFP,
whereas a negligible (2%) proportion of insulin-positive cells
also expressed RFP. Here, we used immunocytochemical anal-
ysis of whole islets to reveal that ZnT8 immunoreactivity was
selectively reduced in the RFP population in PPGCre:ZnT8fl/fl
but not WT mice (Fig. 1C). To more accurately quantify the
degree of deletion of the Slc30a8 allele, RFP-positive islets from
WT and KOmice were dissociated and stained for insulin, glu-
cagon, and ZnT8 before analysis by flow cytometry (Fig. 1, D
andE). Examined in bothWTandKOmice,30%of glucagon-
positive cells were also positive for RFP. Although ZnT8 was
expressed in 99.7% of RFP cells in the WT, there was an
50% (48 	 5%) reduction in immunodetectable ZnT8 in KO
RFP cells. Additionally, we observed a 5–6% reduction of
ZnT8 expression in glucagon RFP cells (Fig. 1F). Consider-
ing the whole population of -cells, the overall decrease in
ZnT8 was about 14% (14 	 1.8%), whereas no deletion was
detected in the -cell population (Fig. 1G). Hence, PPGCre
deletes ZnT8 highly specifically, but only in a minority of
-cells, consistent with previous results (33).
Normal Glucose Homeostasis and Insulin Sensitivity but
Enhanced Response to Hypoglycemia in Vivo and Low Glucose
in Vitro—Intraperitoneal glucose tolerance tests were per-
formed onWT and KO mice at the ages of 8, 10, and 12 weeks
(Fig. 2, A–C), to assess whether the absence of ZnT8 affects
glucose metabolism. Glucose clearance was very similar inWT
and KOmice across all the ages examined. In an effort to exert
some extra stress on the-cell and to checkwhether deletion of
ZnT8 affects insulin sensitivity, insulin tolerance tests were
performed on mice at 8 weeks of age. Blood glucose was mea-
sured at regular intervals and, similarly to intraperitoneal glu-
cose tolerance tests, there were no significant differences
between WT and KO mice (Fig. 2D). Blood was collected at 0
and 15 min for plasma glucagon measurements. The glucagon
levels ofWT andKOmicewere similar at both time points (Fig.
2E).
To assess whether -cell ZnT8 KOmice respond differently
under stimulatory conditions, glucagon secretion experiments
were performed on isolatedWT and KO islets incubated with 1
or 17 mM glucose. At 17 mM glucose, glucagon secretion was
similar between genotypes, whereas at the stimulatory concen-
tration (1 mM glucose), KO islets secreted significantly more
glucagon than islets from WT controls when normalized to
glucagon content per islet (Fig. 2F). No differences in total pan-
creatic glucagon content were apparent between WT and KO
mice (1.6 	 0.35 and 1.4 	 0.1 ng/mg of pancreas, n  3
mice/genotype).
Additionally, WT and KO mice were examined using hypo-
glycemic clamps. During this procedure, mice were rendered
hypoglycemic with the administration of insulin (Fig. 2G) and
were then maintained in a steady, mild hypoglycemic state by
controlling the rate of glucose infusion. Female ZnT8 KO
mice required a lower glucose infusion rate than WT controls
to maintain the same glycemia (Fig. 2H), implying that they
secreted more glucagon than WT controls. Blood samples
taken from these mice showed that, at time 0, KO mice had a
lower basal secretion, but at 90 min after the imposition of
hypoglycemia, they secreted significantly more glucagon than
WT controls (Fig. 2I).
Altered Intracellular Free Zn2 levels, but Unchanged Intra-
cellular Ca2 Responses to Glucose Deprivation, after ZnT8
Deletion—To assess whether deletion of ZnT8 affected the lev-
els of cytoplasmic free Zn2, RFP WT and KO islets were
loaded with the zinc indicator FluoZin-3 (Fig. 3A).Whole islets
were imaged at baseline and after the addition of TPEN (Fig.
ZnT8 in Glucagon Secretion
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3B). These two values were used to give an indication of intra-
cellular free Zn2 concentration. In KO -cells, this value was
significantly reduced as compared with those from WT con-
trols (Fig. 3C).
Given the probable role of ZnT8 to maintain granular zinc
concentrations, we next measured the latter parameter using
the granule-tropic fluorescent Zn2 sensor, Zinpyr-4 (34) (Fig.
3D). As compared with RFP cells inWT islets, those fromKO
FIGURE 1. ZnT8 deletion in cells and assessment of recombination. A, breeding strategy used to generate ZnT8 KOmice and respective controls: (i) for
in vivo comparisons requiring littermate comparisons but not requiring RFP labeling; (ii) to produce RFP-labeled, ZnT8 null -cells; and (iii) to produce
RFP-labeled -cells with WT ZnT8 alleles. B, PCR genotyping of WT and null animals. The bands at330 bp were amplified from the Cre transgene, and the
bands at 220 bp were amplified from -catenin, used as a PCR control. C, ZnT8 immunoreactivity assessed in islets from WT and ZnT8 KO mice. Rabbit
anti-ZnT8 antibody (Mellitech) was added at 1:200 dilution and subsequently revealed with a secondary anti-mouse IgG antibody conjugated to Alexa Fluor
488. Representative images thus showZnT8 in green and endogenous RFP fluorescence in red. Scale bar 10m. Thehistogram shows thepercentage of cells
positive for both RFP and ZnT8. n 80–90 cells from 5–6 islets per genotype. ****, p 0.0001 by Student’s t test. D and E, single cells from RFPWT and KO
islets were fixed, permeabilized, and stained for glucagon, insulin, and ZnT8 (see “Experimental Procedures”). Cells alive immediately before fixation were
gated based on their exclusion of a dead cell marker and analyzed according to the expression of the proteins stained.D and E, representative traces showing
expression analysis for WT (D) and KO (E). Red traces reflect the positive populations, and blue traces reflect the control-negative populations. F, expression of
RFP andZnT8 inWT andKO-cells as a percentage of live cells.G, ZnT8 expression in glucagon and insulin cells fromWTandKOmice. Data aremean	 S.E.,
n 3, two-way ANOVA, *, p 0.01, ***, p 0.0005.
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animals displayed an 50% decrease in apparent free granule
Zn2 (Fig. 3E). We note that the above changes in intracellular
Zn2 distribution are likely to reflect an underestimate of the
change in ZnT8 null -cells, which represent approximately
half of the RFP population (Fig. 1, C–G).
To determine whether changes in intracellular free calcium
([Ca2]i) responses could account for the differences observed
in glucagon secretion, whole islets were incubated with the
trappable intracellular Ca2 indicator Fluo-2 (Fig. 3F). Images
were then captured during perifusion at 1 or 17 mM glucose
(Fig. 3, G and H). When analyzed, spike amplitude and area
under the curve (Fig. 3, I and J) were, however, similar in WT
and KO -cells. Moreover, fast Fourier transform of the indi-
vidual traces showed thatWT and KO -cells oscillated at sim-
ilar frequencies (Fig. 3K).
-CellMass andGene Expression—An increase in pancreatic
-cell mass, or a change in the proportion of-to--cells, could
conceivably contribute to the increased glucagon secretion
observed inKO islets. To investigate this, pancreatic slices were
immunostained for glucagon and insulin and imaged to estab-
lish the - and -cell area (Fig. 4A). In KO mice, there was a
tendency for increased -cell area as compared with the - to
-cell ratio of control mice (Fig. 4B).
RFPWTor KO cells were FACS-sorted for RNA extraction
and gene expression analyses. Similar to the results from flow
cytometry analysis, we observed in KO cells an50% decrease
in ZnT8 expression (Fig. 4C). Importantly, there was no com-
pensatory change in the expression of ZnT transporters in the
absence of ZnT8, which might have explained the observed
lower intracellular free Zn2 levels (Fig. 4C). The expression of
FIGURE 2. Glucose homeostasis and responses to hypoglycemia. A–C, intraperitoneal glucose tolerance tests were performed on WT and ZnT8 KOmice
fed a normal chow diet after an overnight fast at 8 (A), 12 (B), and 16 (C) weeks of age. n  8–15 mice/genotype. D, intraperitoneal insulin tolerance tests
performedon8-week-oldmice fasted for 5 h and injectedwith 0.5 units/kgof insulin. E, plasmaglucagonmeasured at 0 and15min.n13–14mice/genotype.
F, glucose-inhibited glucagon secretion fromWT andZnT8 KO islets incubatedwith high (17mM) and low (1mM) glucose.G, hypoglycemic hyperinsulinemic
clampswereperformedon12-week-oldmice.H, glucose levelsweremonitored, andglucose infusion ratewere adjustedaccordingly. I, plasmaglucagon levels
at 0 and 15 min. n 4–6 mice/genotype. Data are mean	 S.E., two-way repeated measures ANOVA or two-way ANOVA. *, p 0.05, **, p 0.01.
ZnT8 in Glucagon Secretion
AUGUST 28, 2015•VOLUME 290•NUMBER 35 JOURNAL OF BIOLOGICAL CHEMISTRY 21437
 at Im
perial College London on N
ovem
ber 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ZnT8 in Glucagon Secretion
21438 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 35•AUGUST 28, 2015
 at Im
perial College London on N
ovem
ber 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
metallothioneins, cytoplasmic zinc-binding proteins, was like-
wise comparable in each genotype, although a tendency was
apparent for a decrease in MT1 and MT2 expression, in line
with the lowered cytosolic free Zn2 levels (Fig. 4D).
Subcellular Localization of ZnT8 in -Cells—Our previous
studies (15) suggested that ZnT8 was only partially localized to
glucagon secretory granules. Extending these findings, we
observed here using confocal microscopy (Fig. 4E) extensive,
FIGURE 3. Intracellular free Zn2 andCa2 imaging in RFPWTandZnT8KO islets.A, the cell-permeable dye FluoZin-3was used for Zn2 imaging. Scale
bar 50m. B, islets were imaged at baseline (F1) and after perifusion with TPEN (Fmin) to chelate intracellular Zn
2. C, Zn2 levels were determined from the
relative fluorescence (F1/Fmin). AU, absorbance units. D, imaging of intragranular Zn
2 with Zinpyr-4 in WT or KO islets as indicated. E, quantification of the
changes shown in D. CTCF, corrected total cell fluorescence. n 15–20 islets from three mice/genotype, Student’s t test, **, p 0.01. F–H, for Ca2 imaging,
isletswere incubated for 40min. with Fluo2 (F) before being imaged at low (1.0mM) and then high (11mM) glucose. Scale bar 50m.G andH, representative
traces from WT (G) and KO (H) -cells. I, area under the curve (AUC). J, spike amplitude as a percentage of baseline. ve cells, positive cells. K, fast Fourier
transform of individual Ca2 traces. Data are mean	 S.E., n 16–20 islets from four mice, Student’s t test, ***, p 0.0001
FIGURE4.Pancreatichistology.A, pancreatic slices fromWTandZnT8KOmicewere immunostained for insulin andglucagon.B, area is shownas:-cell ratio.
Scale bar 50m. C andD, FACS-sorted RFP cells were used for gene expression analysis. C andD, expression levels of the ZnT family of transporters (C) and
metallothioneins (D) inWTandKOcells. Data aremean	 S.E.,n5–6mice/genotype, comparisonsby two-wayANOVA. *,p0.05, ****,p0.0001.Note that
in C the apparent change in ZnT6 expression was not statistically significant (p
 0.9). E, assessment of colocalization between ZnT8 and glucagon immuno-
reactivity in dissociated wild type -cells. Scale bar 10 m. See the legend for Fig. 1 and “Experimental Procedures” for further details.
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although not complete (Pearson correlation  0.79) overlap
between ZnT8 and glucagon immunoreactivity.
Discussion
The principal aim of the present study was to determine
whether ZnT8 plays a role in the control of glucagon secretion.
Our findings demonstrate a clear role for ZnT8 in restricting
glucagon release at low glucose concentrations both in vivo and
in vitro. Remarkably, deletion of ZnT8 from only a minor frac-
tion (15%) of -cells was sufficient to potentiate the release of
the hormone, suggesting either that the effects at the level of
individual -cells are much larger or, alternatively, that the
deleted cells play a particularly important role in the activity of
the remaining (undeleted) -cells within the islet (36).
Although the present data do not exclude either possibility, we
believe that the latter is the likelier given the augmentation in
secretion required from individual cells to explain the overall
increase in secretion (7-fold in the 15% of recombined cells to
achieve a 2-fold change).
Role of ZnT8 in the Control of Cytosolic and Granular Free
Zn2 Concentration—Measurements of cytosolic Zn2 were
confined here to the use of the small chemical probe, FluoZin-3,
which indicated significant decreases in this parameter after
ZnT8 deletion. We would note that because ZnT8 was only
deleted in about 50% of RFP cells (Fig. 1, C–G), our measure-
ments are likely to underestimate the decrease in free Zn2
engendered by ZnT8 suppression in -cells. Although we were
able to distinguish between signals in -cells from KO versus
WT islets, wewere unable to calibrate these precisely due to the
dynamic range (minimum to maximum) of the probe, which
even surpassed that of our highly sensitive 16-bit EM-CCD
detector (i.e. 166  65,536 possible gray values), as also inde-
pendently noted in Ref. 37. Given the Kd of this probe for Zn2
(15 nM at pH 7.4), this observation is nonetheless compatible
with free Zn2 concentration in WT cells of close to or just
below 1 nM, which was further lowered by ZnT8 deletion. In
this respect, the effects of ZnT8 deletion on free Zn2 appear to
be similar in - as in -cells (38), and suggest a paradoxical role
for ZnT8 in the efflux as well as the uptake of Zn2 into the
secretory granule, the latter evidenced by a clear decrease in
granular free Zn2 in ZnT8 KO mouse -cells (Fig. 3, D and
E). The observed changes in cytosolic and granular Zn2 do not
appear to involve alterations in the expression of other ZnT
family members, or metallothioneins, although we cannot
exclude a possible contribution from changes in Zip (Slc39a)
Zn2 importer levels. Although attempts were made to use
more sophisticated, recombinant, and subcellularly targeted
ratiometric biosensors for Zn2 including eCALWY4 (37), we
observed very poor expression of this probe in-cells after viral
transduction, in-line with the previously observed tropism of
adenoviruses for -cells within the islet (39, 40).
Possible Molecular Mechanisms Involved in the Effects of
ZnT8 on Glucagon Secretion—We noted a small (15%)
increase in-cell:-cell ratio in ZnT8 null mice (Fig. 4B), which
might reflect an action of Zn2 to inhibit cellular proliferation
(41). However, we suspect that the quantitatively more impor-
tant action of ZnT8 is to restrict the release of glucagon stimu-
lated by low glucose concentrations in vitro (Fig. 2F) and in vivo
(Fig. 2I). There are a number of plausible mechanisms through
which ZnT8 might inhibit glucagon secretion at low glucose.
Firstly, it is possible that an action via impaired Zn2 release
from -cells is involved. Our previous studies (17) demon-
strated that ablation of ZnT8 from -cells eliminates the co-re-
lease of Zn2 alongside insulin, and we can predict that a sim-
ilar suppression of Zn2 production occurs from the -cell
after ZnT8 deletion. Could this lead to a lowering of Zn2 levels
locally, with consequences for glucagon secretion? For exam-
ple, this might inhibit KATP channels, reported to be activated
by Zn2 in rat (42) but not mouse (43) -cells to de-inhibit
electrical activity and hence provoke the Ca2 oscillations that
drive secretion. In the rat, convincing evidence was provided
for an inhibitory role for Zn2, based on the ability of the Zn2
chelator Ca2-EDTA to enhance glucagon secretion from the
perfused pancreas (44). On the other hand, our own laboratory
failed to detect any effects of exogenously applied Zn2 on glu-
cagon release from mouse islets (26). Wheeler and colleagues
(45) reported that levels of Zn2 above 10 M inhibited gluca-
gon secretion by amechanismnot involvingKATP channels, but
requiring uptake into the cell and an undefined cytosolic action
of Zn2. Nonetheless, and arguing against a role for changes in
Zn2 secretion, we did not observe in the present studies any
detectable changes in Ca2 dynamics in RFP cells from
ZnT8 KO mice (where 50% were ZnT8 null). Although we
cannot exclude a small change in Ca2 dynamics that was too
small to be detected in the combined (ZnT8, ZnT8) popula-
tion of RFP cells, we note that changes in free cytosolic (Fig. 3,
A–C) and granular (Fig. 3, D and E) free Zn2 were readily
detected between these two groups (RFP and RFP). Further-
more, we obtained no evidence for the existence of two pools of
RFP cells with differing Ca2 spike frequency (results not
shown). Indeed, data from both KO and WT islets passed the
D’Agostino Pearson omnibus normality test, suggestive of
Gaussian distributions.
Might an effect on glucagon packing within granules be
involved? Although we did not see marked abnormalities in
glucagonpacking by electronmicroscopy (results not shown), it
is conceivable that a “looser” agglomeration of glucagonmono-
mers within the granule facilitates the release of the hormone
through the dilating fusion pore, and may mean that a greater
proportion of exocytotic events proceed to completion (i.e. the
granule is fully depleted) before membrane recapture (which
may occur rapidly after release through a “kiss and run” pro-
cess) (46). Our results do, nonetheless, provide clear evidence
for a lowering of cytosolic free Zn2, a change likely to exert
multiple effects on cellular function and exocytosis, ranging
fromchanges in phosphodiesterase activity, andhence intracel-
lular cAMP levels, to altered signaling through receptor phos-
photyrosine phosphatases (47).
Relevance for the Understanding of the Effect of SLC30A8
Alleles on T2D Risk—Recent results from Flannick et al. (21)
have provided a conundrum in terms of our understanding of
the role of SLC30A8/ZnT8 in the control of hormone secretion
and consequently disease risk. As discussed (22), this complex-
ity may arise in part from the interplay between pancreas and
liver, because secreted Zn2 apparently plays an important role
in controlling insulin clearance by the latter (20). The present
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results provide a further level of complexity by showing that
ZnT8 expression in the islet may affect the subsequent metab-
olism (clearance) of both glucagon and insulin. However,
although the control by Zn2 of glucagon clearance by the liver
is a theoretical possibility, the amounts of Zn2 released by
-cells are expected to be far lower than those from -cells
(20%, considering the ratio of - to -cells in the pancreas
(48), and presuming similar maximal rates of release of each
hormone).
Corroborating earlier findings (35), we demonstrate partial
colocalization between ZnT8 and glucagon immunoreactivity
in -cells (Fig. 4E). Interestingly, the degree of colocalization
was somewhat lower than that observed in -cells in our earlier
studies. The identity of the non-dense core granule structures
on which ZnT8 resides in the -cell must at this stage remain
speculative, but may, in part, represent immature granules.
Interestingly, recent data from human islet samples indicate
a strong correlation between the expression of SLC30A8 and
proglucagon in islets, and thus suggest a role for ZnT8 in the
control of proglucagon expression, or vice versa (49). More-
over, SLC30A8 is a target for transcription factor 7-like 2
(TCF7L2) (49), variants of which have the highest impact on
disease risk all of the T2D risk genes discovered so far by
genome-wide association (14). Thus, ZnT8 may be part of a
regulatory network of diabetes susceptibility genes (35). Vari-
ants in these genes may impact both -cell and -cell function
to influence insulin:glucagon ratios and hence T2D risk.
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